Notable Labs

24 articles about Notable Labs

• Notable Labs Reports 2023 Financial Results and Provides a Business Update

  4/12/2024

  Notable Labs, Ltd. reported financial results for the year ended December 31, 2023 and provided a business update.

• Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

  4/9/2024

  Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”) today presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 5178).

• Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform

  4/8/2024

  Notable Labs, Ltd., a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform, presented data related to innovations in the use of cryopreserved samples in the PPMP assay at the American Association for Cancer Research being held in San Diego, CA.

• Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform

  3/5/2024

  Notable Labs, Ltd. announced that the Company will present two posters related to its PPMP platform at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10, 2024 in San Diego, CA.

• Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment

  2/22/2024

  Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”) today announced the advancement of its volasertib Phase 2 program utilizing PPMP to enrich the study population for clinical responders.

• Notable Labs to Participate in JMP Securities Hematology and Oncology Summit

  12/4/2023

  Notable Labs, Ltd. (“Notable”) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced that Thomas Bock, M.D., CEO of Notable Labs, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit taking place virtually on December 5 – 6, 2023.

• Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023

  11/14/2023

  Notable Labs, Ltd. announced that it has filed its Quarterly Report on Form 10-Q containing financial results for the third quarter and nine months ended September 30, 2023.

• Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML

  11/9/2023

  Notable Labs, Inc. announced the publication of data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform to identify more effective pre-hematopoietic stem cell transplantation regimens for the treatment of juvenile myelomonocytic leukemia in the November 9th Issue of the American Society of Clinical Oncology Journal JCO Precision Oncology.

• Notable Labs Closes Merger Transaction With VBL Therapeutics

  10/16/2023

  Notable Labs, Inc., a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, announced the completion of its merger transaction with VBL Therapeutics and associated financing.

• Notable Labs Presents Data Demonstrating PPMP’s Potential to Identify Novel Drug Combinations in JMML at the 2023 EHA Hybrid Congress

  6/9/2023

  Notable Labs, Inc. today presented data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more active investigational pre-hematopoietic stem cell therapy (pre-HCST) regimens.

• Notable Labs to Present Predictive Precision Medicine Platform (PPMP) Data in Juvenile Myelomonocytic Leukemia (JMML) at European Hematology Association (EHA) Hybrid Congress June 8 – 15, 2023

  5/17/2023

  Notable Labs, Inc. today announced an abstract has been accepted for poster presentation at the European Hematology Association (EHA) Hybrid Congress to be held in Frankfurt, Germany on June 8 – 15, 2023.

• Notable Labs Presents Clinical Platform Validation Data at the 2023 American Association for Cancer Research Annual Meeting

  4/18/2023

  Notable Labs, Inc. (“Notable”) today announced clinical data regarding its Predictive Precision Medicine Platform (PPMP) at the 2023 American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida from April 14-19, 2023.

• Notable Labs to Present Results from Clinical Platform Validation Study at the 2023 American Association for Cancer Research (AACR) Annual Meeting

  3/14/2023

  Notable Labs, Inc. (“Notable”) today announced that results from a clinical validation study of its Predictive Precision Medicine Platform (PPMP) will be presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida on April 14-19, 2023.

• Notable to Host July 23 Webinar with Stanford Cancer Institute and MDS Foundation: Emerging Treatment Approaches for Higher Risk Myelodysplastic SyndromesEvent explores current and new treatment options for MDS

  7/13/2020

  Notable , which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today that it is hosting a July 23 webinar titled, “Emerging Treatment Approaches for Higher Risk Myelodysplastic Syndromes.” Speakers from the Stanford Cancer Institute and the MDS Foundation will explore current standards of care for MDS as well as emerging treatment options. The event will be mode

• 

  BioSpace Movers & Shakers, July 10

  7/10/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Notable Appoints Biotech Veteran Joseph Wagner PhD as Chief Scientific OfficerNewly created role intended to help advance compounds through Notable’s scientific development platform

  7/8/2020

  Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today that Joseph Wagner, PhD, has joined the company as Chief Scientific Officer

• Stanford study finds that Notable’s drug sensitivity screening platform can identify potentially useful drugs for MDS patients refractory to standard therapies

  6/23/2020

  First peer-reviewed publication highlighting Notable’s platform published today in Blood Advances

• 

  Notable and MDS Foundation Partner on MDS Trials and New Drug Therapies

  5/1/2020

  Notable will offer a grant to support the MDS Foundation’s education and advocacy efforts, and both companies will work closely to engage physicians, biopharmaceutical companies, health authorities and clinical trial organizations to collaborate on clinical trial designs.

• Notable and MDS Foundation Announce Partnership to Collaborate on Clinical MDS Trials and Advance Drug Therapies for MDS Patients

  4/30/2020

  Notable, which is redefining cancer treatment with its scientific technology platform to rapidly advance drug development, announced a partnership today with the MDS Foundation. 

• Notable Launches The ANSWer Study: An Observational Clinical Trial for Patients with Blood Cancer and Enrolls First Patients

  1/22/2020

  Notable, which is redefining cancer treatment with a clinically validated platform that rapidly advances drug development, is currently enrolling patients in its new observational clinical trial.